News und Analysen
Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
EQS-News: Burcon NutraScience Corp.: Burcon Provides Update on JV, Merit Functional Foods
Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Newron provides H1 2022 results and updates on R&D and business activities
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
Valbiotis informiert über seine Fortschritte und veröffentlicht seinen Finanzbericht für das erste Halbjahr 2022
Valbiotis (FR0013254851 – ALVAL/PEA/KMU-berechtigt) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von
Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022
Regulatory News:
Valbiotis (FR0013254851 – ALVAL / PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic
Pharnext: Findings on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A From ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the American Association of Neuromuscular & Electrodia
Relief Reports Half-Year 2022 Results and Provides Corporate Update
Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Pharnext: Findings From ‘Real-World’ Digital Lifestyle Study, CMT&Me, on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A Published in the Journal of Clinical Neuromuscular Disease
Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss From the European Medicine Agency
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
DGAP-Adhoc: Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate
Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety
Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety
Sensorion to participate in the Inner Ear Biology Workshop in September 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
DGAP-News: Burcon NutraScience Corp.: Burcon Issues Shareholder Letter
Frédéric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors
Regulatory News:
Valbiotis (FR0013254851 - ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Frédéric PELONG, Chief Financial Officer, wird Vorstandmitglied bei Valbiotis
Valbiotis (FR0013254851 - ALVAL, PEA/KMU-qualifiziert) (Paris: ALVAL), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlichen Innovationen zur Vorbeugung und Bekämpfung
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Delisting from Nasdaq Capital Market
DGAP-News: Burcon NutraScience Corp.: Burcon Announces Auditor Resignation and AGM Postponement
Pharnext Appoints Dr. Rob Quinn as Chief Financial Officer
DGAP-News: Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure